Fetal bradycardia following intrauterine platelet transfusion: might elevated levels of donor soluble CD40 ligand play a role?
Yazicioglu
Hasan Fehmi
HF
Unit of Prenatal Diagnosis, Medical University, Lübeck, Germany. hfy@turk.net
Hartwig
Dirk
D
von Witzleben-Schürholz
Esther
E
Neppert
Jürgen
J
Gembruch
Ulrich
U
D000328:Adult; D015415:Biomarkers / Q000097:blood; D001782:Blood Donors; D001805:Blood Transfusion, Intrauterine / Q000009:adverse effects / Q000379:methods; D001919:Bradycardia / Q000175:diagnosis / Q000209:etiology*; D023201:CD40 Ligand / Q000032:analysis*; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006340:Heart Rate, Fetal / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D017713:Platelet Transfusion / Q000009:adverse effects* / Q000379:methods; D011247:Pregnancy; D011256:Pregnancy Outcome; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D015415:Biomarkers; D023201:CD40 Ligand